SCHEMBL24845804

SCHEMBL24845804

CNc1nccc(I)c1OC

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.33
GAK O14976 2/20 0.33
RIPK2 O43353 1/20 0.33
COQ8A Q8NI60 1/20 0.33
NLK Q9UBE8 1/20 0.33
BRD4 O60885 4/20 0.33
ADORA3 P0DMS8 1/20 0.32
ADORA1 P30542 1/20 0.32
ALDH1A1 P00352 5/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
HSD17B10 Q99714 1/20 0.32
CYP2D6 P10635 1/20 0.32
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31
CCR8 P51685 1/20 0.31
KDM4E B2RXH2 2/20 0.31
GAA P10253 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25385708 0.83 MAOA (0.33) MAOAGAKRIPK2COQ8ANLK
SCHEMBL29065349 0.77 ALDH1A1 (0.37) MAOAGAKRIPK2COQ8ANLK
SCHEMBL30608512 0.75 MAOA (0.37) MAOAGAKRIPK2COQ8ANLK
SCHEMBL17563549 0.74 MAOA (0.48) MAOAGAKRIPK2COQ8ANLK
SCHEMBL15112982 0.72 MAOA (0.35) MAOAGAKRIPK2COQ8ANLK
SCHEMBL22440558 0.72 KDM4E (0.39) ALDH1A1TDP1KDM4EGAASMN1; SMN2
SCHEMBL28163267 0.72 NOS2 (0.39) MAOAGAKCCR1CCR5CCR8
SCHEMBL22303095 0.72 KDM4E (0.39) ALDH1A1TDP1KDM4EGAASMN1; SMN2
SCHEMBL15918749 0.72 MAOA (0.35) MAOAGAKRIPK2COQ8ANLK
SCHEMBL22193477 0.72 KDM4E (0.30) ALDH1A1TDP1KDM4EGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250360141-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-11-27 US disclosed
CN-119119062-A Pyridine derivatives having N-linked cyclic substituents as cGAS inhibitors 勃林格殷格翰国际有限公司 2024-12-13 CN disclosed
CN-119119063-A Pyridine derivatives having N-linked cyclic substituents as cGAS inhibitors 勃林格殷格翰国际有限公司 2024-12-13 CN disclosed
US-20240342186-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-10-17 US disclosed
EP-4337326-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS Boehringer Ingelheim International GmbH (DE) 2024-03-20 EP disclosed
CN-117337292-A Pyridine derivatives having N-linked cyclic substituents as cGAS inhibitors 勃林格殷格翰国际有限公司 2024-01-02 CN disclosed
US-20230000878-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240342186-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS CGAS, GLS2, GMPS MAOA 2264/4885GAK 1041/4885RIPK2 1304/4885
US-20250360141-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS CGAS, GLS2, GMPS MAOA 2134/4885GAK 998/4885RIPK2 1289/4885
US-20230000878-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS CGAS, GLS2, GMPS MAOA 2264/4885GAK 1041/4885RIPK2 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.